Exosome-Based Drug Delivery for Neurodegenerative Diseases

Hiroshi Takayuki Tanaka
Center for Lipid-Based Drug Delivery Systems, University of Tokyo, Tokyo, Japan

* Corresponding Author: **Hiroshi Takayuki Tanaka**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 03
May-June 2024
Received: 20-03-2024
Accepted: 22-04-2024
Published: 24-05-2024
Page No: 114-125

Abstract
Neurodegenerative diseases represent a major therapeutic challenge due to the restricted permeability of the blood–brain barrier and the lack of effective drug delivery systems capable of targeting the central nervous system. Exosomes, endogenous extracellular vesicles secreted by virtually all cell types, have emerged as promising biological nanocarriers for therapeutic delivery. These nanoscale vesicles possess inherent biocompatibility, low immunogenicity, and the intrinsic ability to cross biological barriers including the blood–brain barrier. This review provides a comprehensive analysis of exosome-based drug delivery platforms, examining their biogenesis, structural properties, isolation methodologies, engineering strategies, and translational applications in neurodegenerative disorders. We critically evaluate the molecular mechanisms underlying exosome-mediated transport, targeting strategies for neural delivery, and therapeutic applications in Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Furthermore, we discuss safety considerations, manufacturing challenges, regulatory frameworks, and future directions for clinical translation of exosome-based therapeutics.

DOI:

Keywords: Exosomes, Extracellular Vesicles, Drug Delivery, Blood–Brain Barrier, Neurodegenerative Diseases, Nanomedicine, Targeted Therapy

1. Introduction

Neurodegenerative diseases constitute a heterogeneous group of progressive neurological disorders characterized by selective neuronal loss, protein aggregation, neuroinflammation, and functional decline [1]. Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis collectively affect millions of individuals worldwide, imposing substantial economic and social burdens [2]. Despite decades of intensive research, therapeutic options remain largely limited to symptomatic management, with few disease-modifying interventions available [3].

The failure of numerous clinical trials for neurodegenerative diseases can be attributed, in part, to inadequate drug delivery to the central nervous system. The blood–brain barrier represents a formidable obstacle, restricting the passage of approximately 98% of small-molecule drugs and nearly all large-molecule therapeutics including proteins, peptides, and nucleic acids [4]. Conventional drug delivery approaches such as systemic administration result in poor brain penetration, off-target effects, and dose-limiting toxicities. Alternative strategies including direct intracerebroventricular injection, convection-enhanced delivery, and focused ultrasound-mediated barrier disruption carry significant risks and practical limitations [5].

Exosomes have emerged as a paradigm-shifting platform for targeted drug delivery to the central nervous system. These naturally occurring extracellular vesicles, ranging from 30 to 150 nanometers in diameter, mediate intercellular communication by transferring bioactive cargo including proteins, lipids, and nucleic acids between cells [6]. Unlike synthetic nanoparticles, exosomes possess intrinsic biocompatibility, minimal immunogenicity, enhanced circulation stability, and the remarkable ability to traverse the blood–brain barrier through receptor-mediated transcytosis and other mechanisms [7].

Furthermore, exosomes can be engineered to incorporate specific targeting ligands, therapeutic payloads, and imaging agents, enabling precision medicine approaches for neurodegenerative diseases [8].

The rationale for exploiting exosomes as drug delivery vehicles stems from their unique biological properties. Exosomes demonstrate preferential uptake by recipient cells through multiple mechanisms including direct membrane fusion, receptor-ligand interactions, and endocytosis [9]. Their lipid bilayer membrane protects encapsulated cargo from enzymatic degradation and immune surveillance, while their nanoscale dimensions facilitate extravasation and tissue penetration [10]. Moreover, exosomes derived from specific cellular sources can exhibit natural tropism toward particular organs or cell types, providing opportunities for selective neural targeting [11].

2. Structural Features, Biogenesis, and Functional Properties of Exosomes

2.1. Structural Composition and Molecular Characteristics

Exosomes are characterized by a distinctive cup-shaped or spherical morphology when observed by transmission electron microscopy, with a bilayer lipid membrane enriched in cholesterol, sphingomyelin, ceramide, and phosphatidylserine [12]. The membrane composition confers structural rigidity and resistance to mechanical stress, contributing to exosome stability in biological fluids. Proteomic analyses have identified a conserved set of proteins associated with exosomes, including tetraspanins (CD9, CD63, CD81), heat shock proteins (HSP70, HSP90), membrane transport proteins (annexins, Rab GTPases), and components of the endosomal sorting complex required for transport machinery [13].

The cargo composition of exosomes reflects the physiological or pathological state of the parent cell and includes messenger RNA, microRNA, long non-coding RNA, transfer RNA fragments, DNA, metabolites, and diverse protein species [14]. This heterogeneous molecular cargo enables exosomes to modulate recipient cell function through multiple mechanisms including transcriptional regulation, translational control, signal transduction pathway activation, and epigenetic modification [15]. The selective packaging of specific cargo molecules into exosomes is mediated by RNA-binding proteins, post-translational modifications, lipid raft association, and sequence motifs that facilitate sorting [16].

2.2. Biogenesis and Secretion Pathways

Exosome biogenesis is a tightly regulated multistep process initiated by endocytosis and formation of early endosomes. Subsequent invagination of the endosomal membrane generates intraluminal vesicles within multivesicular bodies through mechanisms involving either endosomal sorting complex-dependent or -independent pathways [17]. The endosomal sorting complex machinery, comprising four distinct protein complexes (ESCRT-0, -I, -II, -III), recognizes ubiquitinated cargo proteins and orchestrates membrane budding and vesicle scission [18]. Alternative mechanisms independent of the endosomal sorting complex involve ceramide-mediated membrane curvature, tetraspanin-enriched microdomains, and lipid raft organization [19].

Upon maturation, multivesicular bodies can follow two distinct fates: fusion with lysosomes for cargo degradation or fusion with the plasma membrane for exosome secretion. The decision between these pathways is influenced by cellular context, stress conditions, and signaling cues [20].

Fusion of multivesicular bodies with the plasma membrane is mediated by soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Rab GTPases, particularly Rab27a and Rab27b, which regulate vesicle trafficking and docking [21]. Following membrane fusion, intraluminal vesicles are released into the extracellular space as exosomes, where they can be taken up by neighboring or distant cells.

2.3. Mechanisms of Cellular Uptake and Cargo Delivery

Exosomes employ diverse mechanisms for cellular uptake and cargo transfer, including direct membrane fusion, receptor-mediated endocytosis, phagocytosis, macropinocytosis, lipid raft-mediated internalization, and clathrin- or caveolin-dependent endocytosis [22]. The specific uptake mechanism is determined by exosome surface protein composition, recipient cell type, and microenvironmental factors. Direct fusion with the plasma membrane enables immediate cytoplasmic release of exosomal contents, while endocytic pathways require subsequent escape from endosomal compartments to achieve functional cargo delivery [23].

Following internalization, exosomes can deliver their cargo through multiple pathways. Fusion with endosomal membranes releases luminal contents into the cytoplasm, enabling protein and nucleic acid payloads to exert their biological effects [24]. Alternatively, exosomes may traffic to specific intracellular compartments including lysosomes, the endoplasmic reticulum, or the nucleus, depending on targeting signals present in cargo molecules. The efficiency of cargo delivery is influenced by exosome dosage, exposure duration, recipient cell activation state, and the presence of facilitating factors such as fusogenic peptides or membrane-destabilizing agents [25].

3. Methods for Exosome Isolation, Characterization, and Engineering

3.1. Isolation Techniques and Comparative Analysis

Multiple methodologies have been developed for exosome isolation from biological fluids and cell culture media, each with distinct advantages and limitations regarding yield, purity, scalability, and preservation of biological activity [26]. Ultracentrifugation represents the gold standard technique, employing sequential centrifugation steps at progressively higher speeds (typically 100,000-120,000 × g) to pellet exosomes based on their density and size [27]. While ultracentrifugation enables high-capacity processing, it suffers from lengthy processing times, potential co-isolation of non-exosomal contaminants, and risk of exosome aggregation or structural damage due to high centrifugal forces.

Density gradient ultracentrifugation improves purity by separating exosomes based on their buoyant density (typically 1.13-1.19 g/mL) using sucrose or iodixanol gradients [28]. Size-exclusion chromatography exploits differences in hydrodynamic radius to separate exosomes from smaller molecules and protein aggregates, offering advantages in terms of preserved biological activity and reduced contamination [29]. Immunoaffinity capture utilizes antibodies against exosomal surface markers (CD9, CD63, CD81) immobilized on magnetic beads or chromatography matrices, enabling highly selective isolation of specific exosome subpopulations [30].

Precipitation-based methods employ polyethylene glycol or proprietary polymer solutions to reduce exosome solubility and facilitate collection by low-speed centrifugation. While offering simplicity and high yield, precipitation techniques may co-isolate non-exosomal material and alter exosome physical properties [31]. Microfluidic and tangential flow filtration technologies represent emerging approaches that enable rapid, scalable isolation with minimal sample processing and reduced contamination [32]. The selection of isolation methodology must balance considerations of intended downstream application, starting material volume, required purity, throughput capacity, and available resources.

3.2. Characterization and Quality Control

Comprehensive characterization of isolated exosomes is essential to ensure identity, purity, potency, and reproducibility. The International Society for Extracellular Vesicles recommends minimal experimental requirements including assessment of physical characteristics, biochemical composition, and functional properties [33]. Size distribution analysis by nanoparticle tracking analysis, dynamic light scattering, or tunable resistive pulse sensing provides information on particle concentration and size profiles. Transmission electron microscopy and cryo-electron microscopy enable direct visualization of exosome morphology and structural integrity [34].

Biochemical characterization encompasses detection of exosomal marker proteins by Western blot or flow cytometry, lipid composition analysis by mass spectrometry, and quantification of protein and nucleic acid content [35]. Assessment of contaminants including non-exosomal proteins (albumin, immunoglobulins), lipoproteins, and cellular debris is critical for quality control. Functional assays evaluating biological activity, cellular uptake efficiency, and cargo delivery capacity provide complementary information regarding exosome potency and stability during storage [36].

3.3. Engineering Strategies for Therapeutic Applications

Exosome engineering encompasses strategies to modify cargo composition, surface properties, and targeting capabilities to optimize therapeutic efficacy and specificity. Drug loading approaches include endogenous loading during exosome biogenesis, exogenous loading after isolation, or genetic engineering of donor cells to express therapeutic molecules [37]. Endogenous loading involves transfecting or transducing parent cells with expression vectors encoding therapeutic proteins, peptides, or nucleic acids, which are subsequently packaged into secreted exosomes [38]. This approach preserves native exosome biology but may result in variable loading efficiency and require optimization of expression conditions.

Exogenous loading techniques employ physical or chemical methods to introduce therapeutic cargo into isolated exosomes. Electroporation creates transient membrane pores that enable passive diffusion of small molecules and nucleic acids, while sonication and freeze-thaw cycles disrupt membrane integrity to facilitate loading [39]. Chemical permeabilization using saponin or other agents temporarily increases membrane permeability without causing complete vesicle disruption. Lipofection and calcium chloride transfection adapt established cell transfection protocols for exosome loading [40]. Click chemistry and other bioorthogonal conjugation strategies enable precise attachment of drugs to exosomal surface or luminal proteins.

Surface modification strategies aim to enhance stability, targeting specificity, and barrier penetration. Genetic fusion of targeting peptides or antibody fragments to exosomal membrane proteins enables display of ligands that recognize specific receptors on target cells. Chemical conjugation of polyethylene glycol, peptides, aptamers, or antibodies to exosome surfaces modulates circulation time, biodistribution, and cellular tropism. Incorporation of pH-sensitive or stimuli-responsive elements enables conditional cargo release in response to the tumor microenvironment or other pathological conditions.

Table 1: Sources, Biological Characteristics, and Cargo Composition of Exosomes

Cell Source	Size Range (nm)	Marker Proteins	Cargo Components	Biological Functions
Mesenchymal stem cells	50-150	CD44, CD73, CD90, CD105	miR-21, miR-146a, VEGF, TGF-β	Immunomodulation, tissue regeneration, neuroprotection
Dendritic cells	60-120	MHC-II, CD86, CD80	Antigenic peptides, co-stimulatory molecules	Immune activation, antigen presentation
Neural stem cells	40-100	CD133, nestin, SOX2	Neurotrophic factors, pro-neural miRNAs	Neurogenesis promotion, synaptic plasticity
Macrophages	50-130	CD11b, CD14, CD68	Inflammatory cytokines, miR-155, miR-125b	Inflammation regulation, phagocytosis
Endothelial cells	30-120	CD31, CD144	Angiogenic factors, miR-126, miR-296	Angiogenesis, vascular homeostasis
Tumor cells	40-150	Tumor-associated antigens	Oncogenic proteins, metastatic miRNAs	Tumor progression, metastasis, immune evasion

Table 2: Methods for Exosome Isolation and Characterization

Method	Principle	Advantages	Limitations	Typical Yield	Purity
Ultracentrifugation	Density and size separation	High capacity, established protocol	Time-consuming, equipment-intensive, potential aggregation	Moderate	Moderate
Density gradient	Buoyant density separation	High purity, preserved activity	Complex protocol, low throughput	Low-Moderate	High
Size-exclusion chromatography	Hydrodynamic radius separation	Preserved function, rapid	Limited scalability, dilution effect	Moderate	High
Immunoaffinity capture	Antibody-antigen interaction	High specificity, subpopulation selection	Expensive, limited yield, elution challenges	Low	Very High
Precipitation	Solubility reduction	Simple, high yield, no specialized equipment	Potential contamination, altered properties	High	Low-Moderate
Microfluidics	Integrated separation	Automation, minimal sample, rapid	Device availability, throughput	Low-Moderate	High

4. Cellular and Molecular Mechanisms of Exosome-Mediated Drug Transport

4.1. Pharmacokinetics and Biodistribution

The pharmacokinetic profile of exosomes differs fundamentally from synthetic nanoparticles and conventional pharmaceuticals due to their biological origin and surface characteristics. Following intravenous administration, exosomes exhibit rapid distribution to highly perfused organs including the liver, spleen, lungs, and kidneys, with accumulation kinetics influenced by surface protein composition, size, membrane charge, and parent cell origin. Natural exosomes demonstrate extended circulation half-lives ranging from minutes to several hours, substantially longer than liposomes or polymer nanoparticles of comparable size, attributed to CD47 expression that provides a "don't eat me" signal to phagocytic cells.

Biodistribution studies using radiolabeling, fluorescent dyes, or bioluminescent reporters reveal preferential accumulation in the mononuclear phagocyte system, with hepatic and splenic macrophages representing primary sites of exosome clearance. Surface modification with polyethylene glycol or targeting ligands can redirect biodistribution toward desired tissues while reducing reticuloendothelial system uptake. Interestingly, exosomes derived from specific cellular sources exhibit inherent tissue tropism; brain-derived exosomes demonstrate enhanced brain accumulation compared to peripheral tissue-derived vesicles, suggesting that surface molecules imprint tissue-specific homing properties.

The clearance mechanisms of exosomes involve multiple pathways including macrophage phagocytosis, hepatic metabolism, renal filtration, and biliary excretion. Smaller exosomes may undergo renal elimination, while larger vesicles are predominantly cleared by hepatosplenic mechanisms. Exosome stability in circulation is influenced by interactions with plasma proteins, complement factors, and immune cells. Formation of protein corona on exosome surfaces modulates recognition by cellular receptors and may either enhance or impair targeting efficiency.

4.2. Mechanisms of Blood–Brain Barrier Crossing

The blood–brain barrier comprises specialized brain microvascular endothelial cells interconnected by tight junctions, expressing efflux transporters and exhibiting low pinocytic activity, collectively restricting passage of blood-borne substances into the brain parenchyma. Exosomes employ multiple mechanisms to traverse this formidable barrier, including receptor-mediated transcytosis, adsorptive-mediated transcytosis, and exploitation of endogenous transport pathways. Transcytosis represents the predominant mechanism, involving binding of exosomal surface ligands to endothelial receptors, triggering vesicular internalization, intracellular trafficking, and apical-to-basolateral transport.

Several receptors expressed on brain endothelial cells facilitate exosome transcytosis. Transferrin receptor, highly expressed on blood–brain barrier endothelium, mediates internalization of exosomes displaying transferrin or anti-transferrin receptor antibodies. Low-density lipoprotein receptor-related proteins, particularly LRP1, recognize apolipoprotein-enriched exosomes and mediate their transcytosis. Integrin receptors, including αvβ3 and α5β1, interact with exosomal adhesion molecules and promote endothelial uptake. Neonatal Fc receptor enables transport of immunoglobulin-decorated exosomes across the barrier through pH-dependent binding and release mechanisms.

Engineering strategies to enhance blood–brain barrier penetration exploit these natural transport pathways. Display of rabies virus glycoprotein-derived peptide on exosome surfaces promotes nicotinic acetylcholine receptor-mediated transcytosis. Conjugation of brain-targeting peptides such as Angiopep-2, which binds LRP1, significantly increases brain accumulation following systemic administration. Alternatively, temporary disruption of tight junctions using focused ultrasound combined with microbubbles creates transient openings that facilitate exosome extravasation while minimizing invasiveness compared to direct injection approaches.

4.3. Neural Cell Targeting and Cargo Release

Following barrier crossing, exosomes must navigate the complex brain microenvironment to reach target neural cells. The cellular composition of the central nervous system, including neurons, astrocytes, microglia, oligodendrocytes, and brain endothelial cells, presents opportunities for cell-type-specific targeting through exploitation of distinct surface receptor profiles. Neuronal targeting can be achieved through display of neuron-specific ligands such as neurotrophin receptors, glutamate receptors, or neuron-adhesion molecules. Rabies virus glycoprotein peptide exhibits preferential neuronal tropism, while L1 cell adhesion molecule binds neuronal surface receptors.

Astrocyte-targeted delivery exploits glutamate transporter-1 or glial fibrillary acidic protein as recognition motifs. Microglial targeting utilizes ligands for pattern recognition receptors, scavenger receptors, or purinergic receptors highly expressed on these cells. Oligodendrocyte-specific delivery

may employ antibodies against myelin-associated proteins or platelet-derived growth factor receptor-α. Multiplexed targeting strategies combining multiple ligands enable selective delivery to mixed cell populations or sequential targeting of different cell types.

Upon cellular uptake, efficient cargo release from endosomal compartments into the cytoplasm or other cellular destinations is critical for therapeutic efficacy. Many endocytosed exosomes traffic to lysosomes, where acidic pH and degradative enzymes compromise cargo integrity. Incorporation of endosomal escape motifs, including fusogenic peptides derived from viral proteins, pH-sensitive polymers, or membrane-disrupting agents, facilitates cytoplasmic release. Alternatively, photochemical internalization uses light-activated photosensitizers to disrupt endosomal membranes upon laser irradiation, triggering controlled cargo release.

Table 3: Drug Loading, Surface Modification, and Targeting Strategies

Strategy	Method	Cargo Type	Loading Efficiency	Advantages	Limitations
Endogenous loading	Genetic engineering of donor cells	Proteins, peptides, RNA	Variable (5-30%)	Native packaging, preserved function	Time-consuming, variable yield
Electroporation	Membrane permeabilization	Small molecules, siRNA, miRNA	10-40%	Scalable, versatile	Potential aggregation, reduced activity
Sonication	Membrane disruption	Drugs, nucleic acids	15-35%	Simple, rapid	Structural damage risk
Saponin permeabilization	Chemical permeabilization	Proteins, nucleic acids	20-50%	Gentle, high efficiency	Optimization required
Click chemistry	Bioorthogonal conjugation	Drugs, imaging agents	>80%	Precise, stable attachment	Requires chemical modification
Surface peptide display	Genetic fusion to membrane proteins	Targeting ligands	N/A	Stable expression, specific targeting	Limited to peptides
Chemical conjugation	Covalent attachment	Antibodies, PEG, aptamers	Variable	Versatile, modular	May alter exosome function

5. Strategies for Blood–Brain Barrier Penetration and Neural Targeting

5.1. Passive and Active Targeting Approaches

Passive targeting strategies exploit the enhanced permeability and retention effect observed in certain pathological conditions where blood–brain barrier integrity is compromised, such as in brain tumors, stroke, or neuroinflammation. Under these conditions, fenestrations in the vascular endothelium enable extravasation of nanoscale particles including exosomes. However, passive targeting provides limited specificity and is ineffective in diseases where barrier integrity remains intact. Furthermore, the extent of enhanced permeability varies spatially and temporally, resulting in heterogeneous drug distribution.

Active targeting employs molecular recognition between exosomal surface ligands and receptors expressed on brain endothelial cells or target neural cells. Transferrin receptor targeting represents one of the most extensively studied approaches, utilizing either native transferrin, anti-transferrin receptor antibodies, or transferrin receptor-binding peptides displayed on exosome surfaces. Other receptor-mediated strategies include targeting of insulin receptors, leptin receptors, LDL receptor-related proteins, or nicotinic acetylcholine receptors. Aptamer-based targeting offers advantages of high specificity, low immunogenicity, and ease of synthesis compared to antibody approaches.

Cell-penetrating peptides and brain-targeting peptides provide alternative strategies for blood–brain barrier penetration. Rabies virus glycoprotein-derived peptide (RVG29), comprising 29 amino acids, binds nicotinic acetylcholine receptor and mediates efficient transcytosis across the barrier. TAT peptide, derived from HIV transactivator of transcription protein, enables non-specific cellular penetration through electrostatic interactions with cell membranes. Angiopep-2 peptide specifically recognizes LRP1 and demonstrates superior brain accumulation compared to conventional targeting approaches.

5.2. Receptor-Mediated Transcytosis Mechanisms

Receptor-mediated transcytosis represents the primary mechanism through which engineered exosomes cross the blood–brain barrier. This process initiates with recognition and binding of exosomal targeting ligands to cognate receptors on the luminal surface of brain endothelial cells. Receptor engagement triggers clathrin-mediated or caveolin-mediated endocytosis, internalizing ligand-receptor complexes into endocytic vesicles. Alternatively, micropinocytosis or lipid raft-mediated uptake may contribute to exosome internalization depending on the specific receptor involved.

Following internalization, early endosomes containing exosomes undergo maturation and sorting decisions that determine whether vesicles are recycled to the luminal surface, degraded in lysosomes, or transcytosed to the abluminal membrane. Transcytotic vesicles traffic across the endothelial cell cytoplasm, guided by motor proteins along microtubule and actin networks. The molecular machinery regulating transcytosis includes Rab GTPases (particularly Rab4, Rab5, Rab11), sorting nexins, and endosomal sorting complex components.

Upon reaching the abluminal membrane, transcytotic vesicles fuse and release exosomes into the brain interstitial fluid, from which they can diffuse through the extracellular space and be taken up by neural cells. The efficiency of transcytosis varies depending on multiple factors including receptor expression levels, ligand-receptor affinity, endothelial activation state, and competition with endogenous ligands. Optimization of ligand density on exosome surfaces is critical, as excessive modification may impair natural trafficking mechanisms or trigger immune responses.

5.3. Alternative Blood–Brain Barrier Crossing Strategies

Beyond receptor-mediated transcytosis, several innovative approaches have been developed to facilitate exosome

delivery to the brain. Intranasal administration exploits the direct anatomical connection between the nasal cavity and the brain via olfactory and trigeminal nerve pathways. Following intranasal instillation, exosomes can undergo intraneuronal transport along olfactory nerves to reach the olfactory bulb and subsequently diffuse to other brain regions. This route bypasses the blood–brain barrier entirely, offering advantages of non-invasiveness, reduced systemic exposure, and rapid brain delivery. However, intranasal delivery faces challenges including limited absorption area, mucociliary clearance, and enzymatic degradation in the nasal cavity.

Focused ultrasound combined with intravenously administered microbubbles enables temporary, reversible disruption of the blood–brain barrier at targeted brain regions. Ultrasound energy causes microbubble oscillation, generating mechanical forces that transiently open tight junctions between endothelial cells. During this window, circulating exosomes can extravasate into the brain parenchyma with spatial and temporal precision. This approach has demonstrated safety and efficacy in preclinical models and early-phase clinical trials, offering the potential for repeated, non-invasive barrier modulation.

Convection-enhanced delivery involves stereotactic placement of catheters into specific brain regions, followed by continuous infusion of exosome suspensions under positive pressure. This technique achieves high local drug concentrations and bypasses the blood–brain barrier, but requires neurosurgical intervention and carries risks of catheter-related complications, infection, and hemorrhage. Intrathecal or intracerebroventricular administration delivers exosomes directly into cerebrospinal fluid, enabling distribution throughout the central nervous system via bulk flow and diffusion. While invasive, this approach may be appropriate for diseases affecting the spinal cord or requiring widespread brain distribution.



Fig 1: Biogenesis, Structure, and Intracellular Trafficking of Exosomes



Fig 2: Mechanisms of Exosome-Mediated Drug Delivery Across the Blood–Brain Barrier

6. Therapeutic Applications in Neurodegenerative Diseases

6.1. Alzheimer's Disease

Alzheimer's disease, characterized by progressive cognitive decline, amyloid-beta plaque deposition, neurofibrillary tangle formation, neuroinflammation, and synaptic loss, represents the most prevalent neurodegenerative disorder. Exosome-based therapeutic strategies for Alzheimer's disease encompass delivery of neuroprotective agents, anti-amyloid therapeutics, anti-tau interventions, and immunomodulatory factors. Mesenchymal stem cell-derived exosomes have demonstrated remarkable efficacy in preclinical models, reducing amyloid-beta accumulation, decreasing tau hyperphosphorylation, attenuating neuroinflammation, and improving cognitive function.

Several mechanisms underlie the therapeutic effects of exosomes in Alzheimer's disease. Exosomal cargo includes neprilysin, an amyloid-beta-degrading enzyme, which promotes clearance of pathogenic protein aggregates. MicroRNAs such as miR-29, miR-146a, and miR-let-7 regulate expression of genes involved in amyloid production, tau phosphorylation, and inflammatory responses. Growth factors including brain-derived neurotrophic factor, nerve growth factor, and glial cell line-derived neurotrophic factor support neuronal survival and synaptic plasticity.

Engineered exosomes loaded with small interfering RNA targeting beta-site amyloid precursor protein cleaving enzyme 1 have shown promise in reducing amyloid-beta production. Exosomes functionalized with anti-amyloid-beta antibodies or amyloid-beta-binding peptides can sequester and facilitate clearance of pathogenic protein species. Curcumin-loaded exosomes exhibit enhanced brain delivery and anti-inflammatory activity compared to free drug administration. Recent studies have explored the potential of exosomes to deliver gene therapy vectors, including viral vectors or CRISPR-Cas9 components, for genetic modification of disease-associated pathways.

6.2. Parkinson's Disease

Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra, accumulation of alpha-synuclein aggregates in Lewy bodies, motor dysfunction, and non-motor symptoms. Exosome-based therapies for Parkinson's disease aim to deliver neuroprotective factors, promote dopaminergic neuron survival, reduce alpha-synuclein pathology, and modulate neuroinflammation. Catalase-loaded exosomes have demonstrated protection against oxidative stress-induced neuronal death in cellular and animal models of Parkinson's disease.

Dopamine-loaded exosomes can supplement neurotransmitter levels and alleviate motor symptoms, although challenges remain regarding loading efficiency and release kinetics. Exosomes enriched in microRNAs that target alpha-synuclein expression (miR-7, miR-153) or promote autophagy (miR-21, miR-222) have shown efficacy in reducing protein aggregation and enhancing cellular clearance mechanisms. Glial cell line-derived neurotrophic factor, encapsulated within or displayed on exosomes, promotes dopaminergic neuron survival and neurite outgrowth.

Surface-modified exosomes targeting dopaminergic neurons through dopamine receptor ligands or neuron-specific adhesion molecules enable cell-type-specific delivery. Recent investigations have explored the potential of exosomes derived from dopaminergic neurons or neural stem cells, which may possess inherent tropism toward affected brain regions. Furthermore, exosome-mediated delivery of anti-inflammatory agents or immunomodulatory microRNAs can attenuate microglial activation and neuroinflammatory responses that contribute to disease progression.

6.3. Huntington's Disease

Huntington's disease is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the huntingtin gene, resulting in mutant huntingtin protein aggregation, striatal neuronal loss, and progressive motor, cognitive, and psychiatric disturbances. Exosome-based therapeutic strategies focus on reducing mutant huntingtin expression, enhancing protein clearance, and providing neuroprotection to vulnerable neuronal populations. Small interfering RNA or short hairpin RNA targeting mutant huntingtin mRNA, delivered via engineered exosomes, can achieve selective gene silencing with reduced off-target effects compared to synthetic delivery vehicles.

MicroRNAs such as miR-196a, miR-132, and miR-124, which regulate huntingtin expression or downstream pathological pathways, can be packaged into exosomes for therapeutic delivery. Brain-derived neurotrophic factor-enriched exosomes support striatal neuron survival and function, potentially compensating for reduced neurotrophic support in Huntington's disease. Exosomes derived from mesenchymal stem cells or neural progenitor cells exhibit neuroprotective and anti-inflammatory properties that may slow disease progression.

Challenges specific to Huntington's disease include the need for sustained therapeutic effects given the chronic, progressive nature of the disorder, and the requirement for delivery to both striatal neurons and cortical projection neurons. Repeat administration protocols and development of long-acting exosome formulations are areas of active investigation. Additionally, strategies to enhance autophagy-mediated clearance of mutant huntingtin aggregates through exosome delivery of autophagy-inducing factors represent a promising complementary approach.

6.4. Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis is a fatal motor neuron disease characterized by progressive degeneration of upper and lower motor neurons, leading to muscle weakness, paralysis, and death typically within 3-5 years of diagnosis. The pathogenesis involves protein aggregation (TDP-43, SOD1, FUS), oxidative stress, mitochondrial dysfunction, glutamate excitotoxicity, and neuroinflammation. Exosome-based therapeutics for amyotrophic lateral sclerosis encompass delivery of neurotrophic factors, antioxidants, anti-inflammatory agents, and genetic therapies targeting disease-causing mutations.

Superoxide dismutase 1-loaded exosomes can provide enzymatic antioxidant activity to protect motor neurons from oxidative damage. Brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and vascular endothelial growth factor delivered via exosomes support motor neuron survival and function. Mesenchymal stem cell-derived exosomes have demonstrated efficacy in preclinical models, improving motor function, extending survival, and reducing motor neuron loss through multiple mechanisms including immunomodulation and neurotrophic support.

For patients with familial amyotrophic lateral sclerosis harboring specific genetic mutations, exosome-mediated delivery of gene-silencing RNA targeting mutant SOD1, C9ORF72, or other disease genes offers potential disease-modifying therapy. Challenges include the need to target both spinal cord and brainstem motor neurons, suggesting that intrathecal administration or systemic delivery with enhanced spinal cord penetration may be necessary. The rapidly progressive nature of the disease necessitates early intervention and potent therapeutic effects.

6.5. Multiple Sclerosis

Multiple sclerosis is a chronic autoimmune inflammatory disease of the central nervous system characterized by demyelination, axonal damage, and neurodegeneration. Exosome-based approaches for multiple sclerosis focus on immunomodulation, remyelination promotion, neuroprotection, and anti-inflammatory effects. Regulatory T cell-derived exosomes or exosomes engineered to express immunosuppressive molecules can suppress autoreactive immune responses and reduce disease activity.

Mesenchymal stem cell-derived exosomes exhibit potent immunomodulatory properties, inhibiting proliferation and activation of pathogenic T cells, promoting regulatory T cell differentiation, and modulating antigen-presenting cell function. Oligodendrocyte progenitor cell-derived exosomes may promote remyelination by delivering myelin proteins, lipids, and pro-myelinating microRNAs to demyelinated lesions. Anti-inflammatory exosomes containing specialized pro-resolving mediators or inhibitory cytokines can dampen neuroinflammation and reduce tissue damage.

The relapsing-remitting nature of multiple sclerosis in many patients suggests potential for exosome-based maintenance therapy to prevent relapses and slow progression. Targeting strategies must address both peripheral immune compartments and the central nervous system, potentially requiring combination approaches. The heterogeneity of multiple sclerosis pathophysiology across patients highlights the need for personalized exosome-based interventions tailored to individual disease characteristics and immune profiles.

Table 4: Therapeutic Applications of Exosome-Based Drug Delivery in Neurodegenerative Diseases

Disease	Therapeutic Cargo	Exosome Source	Mechanism of Action	Preclinical Evidence	Clinical Status
Alzheimer's disease	Neprilysin, miR-29, BDNF	MSCs, neural stem cells	Amyloid-β clearance, neuroprotection	Reduced pathology, improved cognition in mice	Preclinical
Alzheimer's disease	Anti-BACE1 siRNA	Engineered exosomes	Reduced amyloid production	Decreased Aβ levels in transgenic models	Preclinical
Parkinson's disease	Catalase, GDNF, miR-7	MSCs, dopaminergic neurons	Antioxidant, neurotrophic support	Protected dopaminergic neurons, improved motor function	Preclinical
Huntington's disease	Anti-HTT siRNA, BDNF	Engineered exosomes, MSCs	Huntingtin silencing, neurotrophic support	Reduced mutant protein, delayed symptom onset	Preclinical
ALS	SOD1, GDNF, immunomodulatory factors	MSCs, engineered exosomes	Antioxidant, neuroprotection, immunomodulation	Extended survival, preserved motor neurons	Preclinical
Multiple sclerosis	Regulatory cytokines, pro-myelinating factors	Regulatory T cells, MSCs	Immunosuppression, remyelination	Reduced disease activity, promoted repair	Preclinical/Phase I

7. Safety Considerations, Manufacturing Challenges, and Regulatory Issues

7.1. Safety and Immunogenicity Assessment

Despite the theoretical advantages of exosomes as naturally derived therapeutic carriers, comprehensive safety assessment remains essential for clinical translation. Key safety considerations include immunogenicity, off-target effects, tumorigenicity, transmission of infectious agents, and unexpected biological activities. Immunogenicity of exosomes depends on multiple factors including cellular source, surface antigen composition, dose, administration route, and recipient immune status. Allogeneic exosomes derived from unmatched donors may elicit antibody responses or T cell-mediated rejection, potentially limiting therapeutic efficacy or causing adverse reactions.

Strategies to minimize immunogenicity include selection of immunoprivileged cell sources such as mesenchymal stem cells, genetic modification to reduce expression of immunogenic antigens, and depletion of major histocompatibility complex molecules from exosome surfaces. Repeated administration protocols require assessment of whether immune responses develop over time and whether immunosuppressive regimens may be necessary for certain applications. Pre-clinical toxicology studies must evaluate acute and chronic toxicity, dose-response relationships, biodistribution, and potential for accumulation in clearance organs.

Tumorigenicity represents a theoretical concern, particularly for exosomes derived from transformed cell lines or tumor cells engineered for therapeutic production. Although exosomes themselves are not replication-competent, they may transfer oncogenic proteins, nucleic acids, or metabolites that could promote proliferation or transformation of recipient cells. Quality control measures must ensure absence of intact cells, viral contamination, bacterial endotoxins, and other adventitious agents in exosome preparations. Long-term follow-up of treated patients will be essential to monitor for delayed adverse events including immune-mediated reactions, organ toxicity, or neoplastic transformation.

7.2. Manufacturing and Scalability Challenges

Large-scale production of clinical-grade exosomes presents substantial technical and logistical challenges that must be addressed for commercial viability. Current laboratory-scale production methods based on cell culture and ultracentrifugation are inadequate for manufacturing the quantities required for clinical trials and therapeutic use. Challenges include achieving consistent exosome yield and quality, establishing reproducible manufacturing processes, ensuring batch-to-batch consistency, scaling up production capacity, and reducing manufacturing costs.

Selection of appropriate cell sources represents a critical

manufacturing decision. Primary cells offer advantages of reduced tumorigenicity risk but suffer from limited expansion capacity, donor variability, and senescence during extended culture. Immortalized cell lines provide unlimited proliferative capacity and consistent phenotype but raise safety concerns regarding transformation potential. Bioreactor systems enabling high-density three-dimensional cell culture under controlled conditions have shown promise for enhancing exosome yield compared to conventional flask-based culture.

Downstream processing represents another major challenge, as efficient, scalable purification methods that preserve exosome integrity and biological activity while achieving regulatory-compliant purity are needed. Tangential flow filtration combined with chromatographic separation offers potential for industrial-scale processing. However, optimization of buffer conditions, processing parameters, and storage conditions requires extensive development. Formulation strategies to enhance exosome stability during storage, including lyophilization or spray-drying, must be validated to ensure maintenance of physical and functional properties.

Quality control and release testing protocols must be established to ensure product identity, purity, potency, and safety. Analytical methods for exosome characterization, including size distribution analysis, protein and nucleic acid quantification, functional assays, and sterility testing, must be validated according to regulatory requirements. Process analytical technology enabling real-time monitoring and control of critical process parameters during manufacturing can improve consistency and quality assurance. Development of standardized reference materials and inter-laboratory validation studies will be essential for harmonization of analytical methodologies across the field.

7.3. Regulatory Framework and Clinical Translation Pathway

The regulatory landscape for exosome-based therapeutics remains evolving, with significant variability across different jurisdictions. In the United States, the Food and Drug Administration classifies exosomes as biological products subject to regulation under Section 351 of the Public Health Service Act. The regulatory pathway depends on multiple factors including the cellular source of exosomes, degree of manipulation, intended therapeutic application, and whether the product is autologous or allogeneic. Minimally manipulated autologous exosomes for homologous use may qualify for streamlined regulatory oversight, while extensively engineered allogeneic exosomes require comprehensive preclinical and clinical development programs.

Regulatory agencies require demonstration of product characterization, manufacturing consistency, preclinical safety and efficacy, and clinical proof-of-concept before approval. Chemistry, manufacturing, and controls documentation must describe the manufacturing process, quality control methods, specifications, stability data, and container-closure system. Preclinical studies must follow Good Laboratory Practice standards and include pharmacology, pharmacokinetics, toxicology, and biodistribution assessments. Clinical trial design should follow established frameworks for cell and gene therapy products, with appropriate patient selection, dose escalation strategies, and safety monitoring.

Challenges specific to exosome regulation include lack of standardized characterization methods, difficulty in defining critical quality attributes, heterogeneity of exosome populations, and limited understanding of long-term safety profiles. Regulatory harmonization across different countries and regions would facilitate international clinical development and commercialization. Engagement with regulatory agencies early in the development process through pre-investigational new drug meetings can help clarify requirements and identify potential obstacles. Post-marketing surveillance and long-term follow-up registries will be important for monitoring real-world safety and effectiveness of approved exosome therapeutics.

8. Future Directions and Research Outlook

8.1. Technological Innovations and Engineering Advances

The future of exosome-based drug delivery will be shaped by technological innovations that address current limitations and expand therapeutic capabilities. Advances in single-vesicle analysis techniques, including super-resolution microscopy, nano-flow cytometry, and single-molecule imaging, will enable unprecedented characterization of exosome heterogeneity and cargo composition. High-throughput screening platforms combining microfluidics, automation, and artificial intelligence-based analysis can accelerate identification of optimal exosome sources, engineering strategies, and therapeutic formulations.

Synthetic biology approaches offer opportunities to create designer exosomes with precisely defined properties. CRISPR-Cas9-mediated genome editing of exosome-producing cells can introduce or delete specific genes to modulate cargo composition, surface protein expression, or functional characteristics. Optogenetic or chemogenetic systems can enable temporal control of exosome secretion or cargo loading, providing on-demand therapeutic release. Hybrid exosome-synthetic nanoparticle systems combining the biological advantages of exosomes with the structural tunability of synthetic materials represent an emerging frontier.

Personalized medicine approaches utilizing patient-derived exosomes or autologous cell sources may improve safety and efficacy while reducing immunogenicity concerns. Multi-functional exosomes capable of simultaneous diagnostic imaging and therapeutic delivery (theranostics) can enable treatment monitoring and dose optimization. Integration of artificial intelligence and machine learning for prediction of exosome biodistribution, identification of optimal targeting ligands, and design of combination therapeutic regimens will accelerate clinical translation. Organ-on-chip and microphysiological systems can provide sophisticated preclinical platforms for evaluating exosome behavior in tissue-like microenvironments.

8.2. Combination Therapies and Multimodal Approaches

Exosome-based therapeutics are likely to achieve maximal benefit when combined with complementary treatment modalities. Combination of exosome-delivered drugs with conventional pharmacotherapy, immunotherapy, or physical interventions may produce synergistic effects. For example, exosomes carrying chemo sensitizing agents combined with standard chemotherapy for brain metastases could overcome drug resistance and enhance therapeutic efficacy. Sequential administration of immunomodulatory exosomes followed by checkpoint inhibitor antibodies might improve anti-tumor

immune responses in brain malignancies.

Multi-cargo exosomes loaded with multiple therapeutic agents targeting different pathological pathways represents another promising strategy. Co-delivery of anti-amyloid and anti-tau therapeutics in Alzheimer's disease, or combinations of neuroprotective and anti-inflammatory agents in multiple sclerosis, could address disease complexity more comprehensively than single-agent approaches. Time-programmed sequential release of different cargo molecules from engineered exosomes can provide temporally optimized therapeutic effects matching disease kinetics.

Integration of exosome delivery with gene therapy, cell therapy, or regenerative medicine approaches offers exciting possibilities. Exosomes could serve as adjuvants to enhance engraftment and function of transplanted stem cells, or as vehicles for delivering reprogramming factors to induce endogenous neural regeneration. Combination with physical modalities such as transcranial magnetic stimulation or deep brain stimulation may enhance therapeutic outcomes through synergistic mechanisms. Development of rationally designed combination regimens based on systems biology and network analysis of disease pathways will require interdisciplinary collaboration and sophisticated experimental design.

8.3. Translation to Clinical Practice

Despite promising preclinical data, translation of exosome-based therapeutics to clinical practice faces significant hurdles. As of 2025, only a limited number of clinical trials investigating exosome-based therapies for neurodegenerative diseases have been initiated, most in early phases. Careful patient selection, including stratification by disease stage, genetic profile, and biomarker status, will be critical for demonstrating clinical benefit. Development of companion diagnostics to identify patients most likely to respond to exosome therapy could facilitate precision medicine implementation.

Clinical trial design must address unique aspects of exosome therapeutics including optimal dosing regimens, administration routes, and endpoints for efficacy assessment. Surrogate biomarkers such as cerebrospinal fluid protein levels, neuroimaging measures, or blood-based biomarkers may enable earlier detection of therapeutic effects compared to clinical outcome measures. Adaptive trial designs with predefined decision rules for dose modification or patient enrichment can improve efficiency and accelerate development timelines.

Real-world evidence generation through post-approval registries and observational studies will be essential for understanding long-term safety, effectiveness in diverse patient populations, and optimal use patterns. Health economics and outcomes research evaluating cost-effectiveness compared to existing therapies will inform reimbursement decisions and healthcare system adoption. Patient engagement and education regarding the potential benefits and limitations of exosome-based therapies will be important for informed decision-making and realistic expectations. Ultimately, successful clinical translation will require sustained investment, collaborative partnerships between academia and industry, supportive regulatory frameworks, and commitment to rigorous scientific evaluation.

9. Conclusion

Exosome-based drug delivery represents a transformative paradigm for treatment of neurodegenerative diseases, offering unique advantages of biocompatibility, blood–brain barrier penetration, and targeted therapeutic delivery. Significant progress has been made in understanding exosome biology, developing engineering strategies, and demonstrating preclinical efficacy across multiple disease models. Natural exosomes possess intrinsic properties that make them attractive therapeutic carriers, while engineered exosomes enable precise control of cargo composition, targeting specificity, and pharmacological properties. Applications in Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis have shown promising results in preclinical studies, with some early-phase clinical trials underway.

However, substantial challenges remain before exosome-based therapeutics can achieve widespread clinical implementation. Manufacturing scalability, batch-to-batch consistency, regulatory approval pathways, and long-term safety profiles require further investigation and optimization. Standardization of isolation methods, characterization techniques, and quality control assays is essential for advancing the field. Mechanistic understanding of exosome-target cell interactions, intracellular trafficking, and cargo release mechanisms must be deepened to guide rational therapeutic design. Cost-effectiveness analyses and healthcare system integration planning will be necessary to ensure accessibility and sustainability.

Looking forward, technological innovations in exosome engineering, combination therapeutic strategies, and personalized medicine approaches hold great promise for realizing the full potential of exosome-based drug delivery. Interdisciplinary collaboration among biologists, clinicians, engineers, regulatory scientists, and industry partners will be critical for overcoming existing barriers and translating preclinical advances into effective therapies. With continued research investment, rigorous scientific evaluation, and collaborative effort, exosome-based therapeutics may fundamentally transform the treatment landscape for neurodegenerative diseases, offering hope to millions of patients and families affected by these devastating disorders.

10. References

1. Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2017;9(7):a028035.
2. Feigin VL, Vos T, Nichols E, *et al*. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255-265.
3. Cummings J, Lee G, Zhong K, *et al*. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1):e12179.
4. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
5. Kariolis MS, Wells RC, Getz JA, *et al*. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359.
6. Théry C, Witwer KW, Aikawa E, *et al*. Minimal information for studies of extracellular vesicles 2018

(MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the minimal information for studies of extracellular vesicles 2014 (MISEV2014). J Extracell Vesicles. 2018;7(1):1535750.
7. Alvarez-Erviti L, Seow Y, Yin H, *et al*. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341-345.
8. Luan X, Sansanaphongpricha K, Myers I, *et al*. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017;38(6):754-763.
9. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3:24641.
10. Kamerkar S, LeBleu VS, Sugimoto H, *et al*. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498-503.
11. Hoshino A, Costa-Silva B, Shen TL, *et al*. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329-335.
12. Skotland T, Hessvik NP, Sandvig K, Llorente A. Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J Lipid Res. 2019;60(1):9-18.
13. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
14. Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487-514.
15. O'Brien K, Breyne K, Ughetto S, *et al*. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21(10):585-606.
16. Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, *et al*. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4:2980.
17. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228.
18. Vietri M, Radulovic M, Stenmark H. The many functions of ESCRTs. Nat Rev Mol Cell Biol. 2020;21(1):25-42.
19. Trajkovic K, Hsu C, Chiantia S, *et al*. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244-1247.
20. Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75(2):193-208.
21. Ostrowski M, Carmo NB, Krumeich S, *et al*. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1):19-30.
22. McKelvey KJ, Powell KL, Ashton AW, *et al*. Exosomes: mechanisms of uptake. J Circ Biomark. 2015;4:7.
23. Joshi BS, de Beer MA, Giepmans BNG, Zuhorn IS. Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano. 2020;14(4):4444-4455.
24. Mathieu M, Névo N, Jouve M, *et al*. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. Nat Commun. 2021;12(1):4389.
25. Haney MJ, Klyachko NL, Zhao Y, *et al*. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015;207:18-30.
26. Gardiner C, Di Vizio D, Sahoo S, *et al*. Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. J Extracell Vesicles. 2016;5:32945.
27. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3.22.
28. Kowal J, Arras G, Colombo M, *et al*. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016;113(8):E968-E977.
29. Böing AN, van der Pol E, Grootemaat AE, *et al*. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles. 2014;3:23430.
30. Tauro BJ, Greening DW, Mathias RA, *et al*. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods. 2012;56(2):293-304.
31. Rider MA, Hurwitz SN, Meckes DG Jr. ExtraPEG: a polyethylene glycol-based method for enrichment of extracellular vesicles. Sci Rep. 2016;6:23978.
32. Chen C, Skog J, Hsu CH, *et al*. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip. 2010;10(4):505-511.
33. Witwer KW, Buzás EI, Bemis LT, *et al*. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2:20360.
34. Yuana Y, Sturk A, Nieuwland R. Extracellular vesicles in physiological and pathological conditions. Blood Rev. 2013;27(1):31-39.
35. Webber J, Clayton A. How pure are your vesicles? J Extracell Vesicles. 2013;2:19861.
36. Royo F, Théry C, Falcón-Pérez JM, *et al*. Methods for separation and characterization of extracellular vesicles: results of a worldwide survey performed by the ISEV rigor and standardization subcommittee. Cells. 2020;9(9):1955.
37. Johnsen KB, Gudbergsson JM, Skov MN, *et al*. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta. 2014;1846(1):75-87.
38. Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015;290(13):8166-8172.
39. Fuhrmann G, Serio A, Mazo M, *et al*. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015;205:35-44.
40. Sato YT, Umezaki K, Sawada S, *et al*. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep. 2016;6:21933.